Zai Lab Ltd 8-K

What Happened
Zai Lab Limited filed an 8‑K reporting the results of its 2026 Annual General Meeting held June 17, 2026. Shareholders holding 550,281,867 ordinary shares (present in person, virtually or by proxy) voted on directors, auditor appointment, executive compensation (advisory) and general share issuance/repurchase mandates. All items except none failed — Proposals 1–11 and 13–14 were approved; Proposal 12 (advisory vote on named executive officer compensation) was also approved on an advisory basis.

Key Details

• Total shares present: 550,281,867 (more than one‑tenth of voting share capital as of record date April 16, 2026).
• Directors re‑elected (terms to 2027): Samantha (Ying) Du; John D. Diekman; Richard Gaynor; Nisa Leung; William Lis; Scott Morrison; Leon O. Moulder Jr.; Michel Vounatsos; Peter Wirth. All carried as ordinary resolutions.
• Advisory "say‑on‑pay" (Proposal 12): For 392,663,823; Against 154,589,463; Abstentions 3,028,581 — roughly 72% For vs. 28% Against on votes cast.
• Auditor and mandates: KPMG LLP and KPMG appointed as auditors (For 547,252,626); board authorized to (a) allot/issue up to 10% of issued ordinary shares and/or ADSs/resell treasury shares, and (b) repurchase up to 10% of issued ordinary shares and/or ADSs — both general mandates were approved.

Why It Matters

• Governance continuity: Re‑election of the full slate of directors and appointment of KPMG maintain board and auditor continuity, which can reduce near‑term governance uncertainty.
• Shareholder approval of issuance and repurchase mandates (each up to 10%) gives the board flexibility for capital-raising, employee programs or buybacks through the 2027 annual meeting.
• The advisory say‑on‑pay passed but with significant opposition (~28% against), a signal investors may watch for future executive compensation disclosures and potential engagement.